{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:10:39Z","timestamp":1791202239259,"version":"4.2.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T00:00:00Z","timestamp":1400198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s00280-014-2476-y","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T09:20:28Z","timestamp":1400145628000},"page":"151-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide"],"prefix":"10.1007","volume":"74","author":[{"given":"Wendi V.","family":"Rodrigueza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Woolliscroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul-Shukkur","family":"Ebrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Forgey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"McGovren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerold","family":"Endert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Holewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro","family":"Aboukameel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Bisgaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Messmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elzbieta","family":"Izbicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Streeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Stiegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Monsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina P.","family":"Sooch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Panzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal C.","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayad","family":"Al-Katib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,16]]},"reference":[{"key":"2476_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1083\/jcb.124.1.1","volume":"124","author":"JC Reed","year":"1994","unstructured":"Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1\u20136","journal-title":"J Cell Biol"},{"key":"2476_CR2","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2011.37.0981","volume":"30","author":"MS Davids","year":"2012","unstructured":"Davids MS, Letai A (2012) Targeting the B-cell lymphoma\/leukemia 2 family in cancer. J Clin Oncol 30:3127\u20133135","journal-title":"J Clin Oncol"},{"key":"2476_CR3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/j.1460-2075.1988.tb02791.x","volume":"7","author":"M Seto","year":"1988","unstructured":"Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S et al (1988) Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 7:123\u2013131","journal-title":"EMBO J"},{"key":"2476_CR4","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1038\/sj.onc.1205483","volume":"21","author":"CA Heckman","year":"2002","unstructured":"Heckman CA, Mehew JW, Boxer LM (2002) NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21:3898\u20133908","journal-title":"Oncogene"},{"key":"2476_CR5","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1073\/pnas.84.5.1329","volume":"84","author":"Y Tsujimoto","year":"1987","unstructured":"Tsujimoto Y, Bashir MM, Givol I, Cossman J, Jaffe E, Croce CM (1987) DNA rearrangements in human follicular lymphoma can involve the 5\u2032 or the 3\u2032 region of the bcl-2 gene. Proc Natl Acad Sci USA 84:1329\u20131331","journal-title":"Proc Natl Acad Sci USA"},{"key":"2476_CR6","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1349-7006.2001.tb01183.x","volume":"92","author":"N Yonetani","year":"2001","unstructured":"Yonetani N, Ueda C, Akasaka T, Nishikori M, Uchiyama T, Ohno H (2001) Heterogeneous breakpoints on the immunoglobulin genes are involved in fusion with the 5\u2032 region of BCL-2 in B-cell tumors. J Cancer Res 92:933\u2013940","journal-title":"J Cancer Res"},{"key":"2476_CR7","doi-asserted-by":"crossref","first-page":"44095","DOI":"10.1074\/jbc.M111.265439","volume":"286","author":"BF Pickering","year":"2011","unstructured":"Pickering BF, Yu D, Van Dyke MW (2011) Nucleolin protein interacts with microprocessor complex to affect biogenesis of microRNAs 15a and 16. J Biol Chem 286:44095\u201344103","journal-title":"J Biol Chem"},{"key":"2476_CR8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/emmm.201100209","volume":"4","author":"MV Iorio","year":"2012","unstructured":"Iorio MV, Croce CM (2012) MicroRNA involvement in human cancer. EMBO Mol Med 4:143\u2013159","journal-title":"EMBO Mol Med"},{"key":"2476_CR9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/annonc\/mdl280","volume":"17","author":"TR Wilson","year":"2006","unstructured":"Wilson TR, Longley DB, Johnston PG (2006) Chemoresistance in solid tumours. Ann Oncol 17:315\u2013324","journal-title":"Ann Oncol"},{"key":"2476_CR10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1517\/14728222.2013.733001","volume":"17","author":"S Thomas","year":"2013","unstructured":"Thomas S, Quinn BA, Das SK, Dash R, Emdad L et al (2013) Targeting the Bcl-2 family for cancer therapy. Exp Opin Cancer Targets 17:61\u201375","journal-title":"Exp Opin Cancer Targets"},{"key":"2476_CR11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4161\/epi.6.2.13640","volume":"6","author":"NP Blackledge","year":"2011","unstructured":"Blackledge NP, Klose RJ (2011) CpG island chromatin: a platform for gene regulation. Epigenetics 6:147\u2013152","journal-title":"Epigenetics"},{"key":"2476_CR12","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1101\/gad.2037511","volume":"25","author":"AM Deaton","year":"2011","unstructured":"Deaton AM, Bird A (2011) CpG islands and regulation of transcription. Genes Dev 25:1010\u20131022","journal-title":"Genes Dev"},{"key":"2476_CR13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nature11232","volume":"489","author":"RE Thurman","year":"2012","unstructured":"Thurman RE, Rynes E, Humbert R, Vierstra H, Maurano MT (2012) The accessible chromatin landscape of the human genome. Nature 489:75\u201382","journal-title":"Nature"},{"key":"2476_CR14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.genom.7.080505.115623","volume":"7","author":"GA Maston","year":"2006","unstructured":"Maston GA et al (2006) Transcriptional regulatory elements in the human genome. Annu Rev Genomics Hum Genet 7:29\u201359","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"2476_CR15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nmeth890","volume":"3","author":"PJ Sabo","year":"2006","unstructured":"Sabo PJ, Kuehn MS, Thurman R, Johnson BE, Johnson BE et al (2006) Genome-scale mapping of DNase I sensitivity in vivo using tiling DNA microarrays. Nat Methods 3:511\u2013518","journal-title":"Nat Methods"},{"key":"2476_CR16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2199-12-33","volume":"12","author":"V Brazda","year":"2011","unstructured":"Brazda V, Laister RC, Jagelska EB, Arrowsmith C (2011) Cruciform structures are a common DNA feature important for regulating biological processes. BMC Mol Biol 12:33\u201348","journal-title":"BMC Mol Biol"},{"issue":"8","key":"2476_CR17","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1351\/PAC-CON-09-09-29","volume":"82","author":"S Kendrick","year":"2010","unstructured":"Kendrick S, Hurley LH (2010) The role of G-quadruplex\/i-motif secondary structures as cis-acting regulatory elements. Pure Appl Chem 82(8):1609\u20131621","journal-title":"Pure Appl Chem"},{"key":"2476_CR18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/1947601910377493","volume":"1","author":"TA Brooks","year":"2010","unstructured":"Brooks TA, Hurley LH (2010) Targeting MYC Expression through G-Quadruplexes. Genes Cancer 1:641\u2013649","journal-title":"Genes Cancer"},{"key":"2476_CR19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd3428","volume":"10","author":"S Balasubramanian","year":"2011","unstructured":"Balasubramanian S, Hurley LH, Neidle S (2011) Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nat Rev Drug Discov 10:261\u2013275","journal-title":"Nat Rev Drug Discov"},{"key":"2476_CR20","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1128\/MCB.13.6.3686","volume":"13","author":"SL Young","year":"1993","unstructured":"Young SL, Korsmeyer SJ (1993) A negative regulatory element in the bcl-2 5\u2032-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol 13:3686\u20133697","journal-title":"Mol Cell Biol"},{"key":"2476_CR21","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1128\/MCB.15.7.3840","volume":"15","author":"HM Chen","year":"1995","unstructured":"Chen HM, Boxer LM (1995) P1 binding sites are negative regulators of bcl-2 expression in pre-B cells. Mol Cell Biol 15:3840\u20133847","journal-title":"Mol Cell Biol"},{"key":"2476_CR22","first-page":"3131","volume":"54","author":"T Miyashita","year":"1994","unstructured":"Miyashita T, Harigai M, Hanada M, Reed JC (1994) Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54:3131\u20133135","journal-title":"Cancer Res"},{"key":"2476_CR23","doi-asserted-by":"crossref","first-page":"6720","DOI":"10.1038\/onc.2008.286","volume":"27","author":"H Duan","year":"2008","unstructured":"Duan H, Xiang H, Ma L, Boxer LM (2008) Functional Long-range Interactions of the IgH 3\u2032 Enhancers with the bcl-2 Promoter Region in t(14;18) Lymphoma Cell. Oncogene 27:6720\u20136728","journal-title":"Oncogene"},{"key":"2476_CR24","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.bpj.2011.03.048","volume":"100","author":"E Siepi","year":"2011","unstructured":"Siepi E, Lutz S, Meyer S, Panzner S (2011) An ion switch regulates fusion of charged membranes. Biophys J 100:2412\u20132421","journal-title":"Biophys J"},{"key":"2476_CR25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jconrel.2012.11.008","volume":"165","author":"A Arranz","year":"2013","unstructured":"Arranz A, Reinsch C, Papadakis KA, Dieckmann A, Rauchhaus U et al (2013) Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes. J Control Release 165:163\u2013172","journal-title":"J Control Release"},{"key":"2476_CR26","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/art.24434","volume":"60","author":"E Andreakos","year":"2009","unstructured":"Andreakos E, Rauchhaus U, Stavropoulos A, Endert G, Wendisch V et al (2009) Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis. Arthritis Rheum 60:994\u20131005","journal-title":"Arthritis Rheum"},{"key":"2476_CR27","doi-asserted-by":"crossref","unstructured":"Tolcher A, Rodrigueza WV, Rasco DW et al (2013) A Phase 1 Study of the BCL2 targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2013 (in press)","DOI":"10.1007\/s00280-013-2361-0"},{"issue":"3","key":"2476_CR28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1081\/LPR-120014761","volume":"12","author":"A Wagner","year":"2002","unstructured":"Wagner A, Vorauer-Uhl K, Kreismayr G, Katinger H (2002) The crossflow injection technique\u2014an improvement of the ethanol injection method. J Liposome Res 12(3):259\u2013270","journal-title":"J Liposome Res"},{"key":"2476_CR29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0939-6411(02)00062-0","volume":"54","author":"A Wagner","year":"2002","unstructured":"Wagner A, Vorauer-Uhl K, Katinger H (2002) Liposome produced in a pilot scale: production, purification and efficiency aspects. Eur J Pharm Biopharm 54:213\u2013219","journal-title":"Eur J Pharm Biopharm"},{"key":"2476_CR30","first-page":"717","volume":"44","author":"TH Corbett","year":"1984","unstructured":"Corbett TH, Roberts BJ, Leopold WR, Peckman JC, Wilkoff LJ et al (1984) Induction and Chemotherapeutic Response of Two Transplantable Ductal Adenocarcinomas of the Pancreas in C57BL\/6 Mice. Cancer Res 44:717\u2013726","journal-title":"Cancer Res"},{"key":"2476_CR31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0165-4608(93)90132-6","volume":"70","author":"RM Mohammad","year":"1993","unstructured":"Mohammad RM, Mohamed AN, Smith MR, Jawadi N, Al-Katib A (1993) A unique EBV- negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;8) and t(8;11). Cancer Genetics Cytogenetics 70:62\u201367","journal-title":"Cancer Genetics Cytogenetics"},{"key":"2476_CR32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4161\/cbt.1.4.4","volume":"1","author":"N Dias","year":"2002","unstructured":"Dias N, Stein C (2002) Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 1:347\u2013355","journal-title":"Mol Cancer Ther"},{"key":"2476_CR33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nature02889","volume":"431","author":"H Kawasaki","year":"2004","unstructured":"Kawasaki H, Taira K (2004) Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature 431:211\u2013217","journal-title":"Nature"},{"key":"2476_CR34","doi-asserted-by":"crossref","first-page":"7244","DOI":"10.1158\/1078-0432.CCR-04-0642","volume":"10","author":"CM Rudin","year":"2004","unstructured":"Rudin CM, Marshall JL, Huang CH, Kindler HL, Zhang C et al (2004) Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res 10:7244\u20137251","journal-title":"Clin Cancer Res"},{"key":"2476_CR35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00280-004-0944-5","volume":"56","author":"BN Fahy","year":"2005","unstructured":"Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ (2005) Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 56:46\u201354","journal-title":"Cancer Chemother Pharmacol"},{"key":"2476_CR36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/1061186021000072447","volume":"10","author":"A Gabizon","year":"2002","unstructured":"Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT (2002) Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in Murine Models. J Drug Target 10:539\u2013548","journal-title":"J Drug Target"},{"key":"2476_CR37","first-page":"1393","volume":"4","author":"GF Sullivan","year":"1998","unstructured":"Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM, Hait WN (1998) The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 4:1393\u20131403","journal-title":"Clin Cancer Res"},{"key":"2476_CR38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nchembio725","volume":"1","author":"BA Janowski","year":"2005","unstructured":"Janowski BA, Huffman KE, Schwartz JC, Ram R, Hardy D et al (2005) Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs. Nat Chem Biol 1:216\u2013222","journal-title":"Nat Chem Biol"},{"key":"2476_CR39","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s00109-002-0366-y","volume":"80","author":"CM Liu","year":"2002","unstructured":"Liu CM, Lui DP, Liang CC (2002) Oligonucleotide-mediated gene repair at DNA level: the potential applications for gene therapy. J Mol Med 80:620\u2013628","journal-title":"J Mol Med"},{"key":"2476_CR40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","volume":"11","author":"R Kole","year":"2012","unstructured":"Kole R, Krainer AR, Altman S (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discovery 11:125\u2013140","journal-title":"Nat Rev Drug Discovery"},{"key":"2476_CR41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1758-907X-1-14","volume":"1","author":"AK Vaishnaw","year":"2010","unstructured":"Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D et al (2010) Review: status report on RNAi therapeutics. Silence 1:14\u201326","journal-title":"Silence"},{"key":"2476_CR42","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.chembiol.2012.07.011","volume":"19","author":"GF Deleavey","year":"2012","unstructured":"Deleavey GF, Damha MJ (2012) Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol 19:937\u2013954","journal-title":"Chem Biol"},{"key":"2476_CR43","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.146.12.4234","volume":"146","author":"A Chonn","year":"1991","unstructured":"Chonn A, Cullis PR, Devine DV (1991) The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 146:4234\u20134241","journal-title":"J Immunol"},{"key":"2476_CR44","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M et al (2010) Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. Mol Ther 18:1357\u20131364","journal-title":"Mol Ther"},{"key":"2476_CR45","first-page":"235","volume-title":"Rapid freezing, freeze fracture and deep etching (techniques in modern biomedical microscopy)","author":"MJ Hope","year":"1995","unstructured":"Hope MJ, Rodrigueza WV (1995) Membrane lipids and model membrane systems. In: Severs N, Shotton D (eds) Rapid freezing, freeze fracture and deep etching (techniques in modern biomedical microscopy). Wiley, New York, pp 235\u2013253"},{"key":"2476_CR46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0005-2736(93)90270-A","volume":"1153","author":"WV Rodrigueza","year":"1993","unstructured":"Rodrigueza WV, Pritchard PH, Hope MJ (1993) Influence of size and composition on the cholesterol mobilizing properties of liposomes in vivo. Biochim Biophys Acta 1153:9\u201319","journal-title":"Biochim Biophys Acta"},{"key":"2476_CR47","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.ATV.17.10.2132","volume":"17","author":"WV Rodrigueza","year":"1997","unstructured":"Rodrigueza WV, Mazany KE, Essenburg AE, Pape ME, Bisgaier CL, Williams K (1997) Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools: implications for the treatment of atherosclerosis. Arterioscler Thromb Vasc Biol 17:2132\u20132139","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2476_CR48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/nn900002m","volume":"3","author":"OC Farokhzad","year":"2009","unstructured":"Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS Nano 3(1):16\u201320","journal-title":"ACS Nano"},{"issue":"6","key":"2476_CR49","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1517\/14712598.1.6.923","volume":"1","author":"N Maurer","year":"2001","unstructured":"Maurer N, Fenske DB, Cullis PR (2001) Developments in liposomal drug delivery systems. Expert Opin Biol Ther 1(6):923\u2013947","journal-title":"Expert Opin Biol Ther"},{"key":"2476_CR50","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1158\/1078-0432.CCR-11-0267","volume":"17","author":"J Iqbal","year":"2011","unstructured":"Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM et al (2011) BCL-2 Predicts Survival in Germinal Center B-cell-like DLBCL Treated with CHOP-like Therapy and Rituximab. Clin Cancer Res 17:7785\u20137795","journal-title":"Clin Cancer Res"},{"key":"2476_CR51","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","volume":"30","author":"TM Green","year":"2012","unstructured":"Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A (2012) Immunohistochemical Double Hit Score is a Strong Predictor of Outcome in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus Cyclophsphamide, Doxorubicin, Vincristine, and Prednisone. J Clin Oncol 30:3460\u20133467","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2476-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2476-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2476-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T04:27:19Z","timestamp":1689222439000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2476-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,16]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["2476"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2476-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,16]]}}}